Phio Pharmaceuticals announced it is presenting new data at the 27th Annual Meeting of the American Society of Cell and Gene Therapy, ASCGT, about its lead clinical product candidate, PH-762, an INTASYL compound. Preclinical studies demonstrate that PH-762 is effective in silencing PD-1, boosting immune response, and inhibiting tumor growth. PH-762 is currently being studied in a U.S. clinical trial to assess safety and efficacy in specific skin cancers. The data will be presented at the American Society of Cell and Gene Therapy on May 8th in Baltimore, Maryland. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHIO:
- National Spotlight Features Phio’s Innovative RNAi Technology Platform
- Phio Pharmaceuticals says INTASYL platform to be focus of ‘Viewpoint’
- Phio Pharmaceuticals on the Brink: Nasdaq Delisting Looms Over Falling Stock Prices
- Phio Pharmaceuticals reports FY23 EPS ($5.20) vs ($10.10) last year
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update